What DreamCIS does

DreamCIS is a Seoul-headquartered, KOSDAQ-listed clinical research organization (ticker 223250) founded in 2000 and operating as a strategic subsidiary of Chinese CRO Tigermed. The company provides a full-lifecycle drug development platform spanning Phase 1-4 clinical trials, non-interventional studies (NIS), registry post-marketing studies (r-PMS), and multi-regional clinical trials (MRCT), with a documented track record of 714 clinical trials, 304 NIS, and 391 r-PMS across oncology (125 trials), cardiovascular (231), endocrinology (150), and rare disease (62). Core platforms include clinical development services, Site Management Organization (SMO) operations, healthcare regulatory consulting, medical device services (CE-MDR and FDA global registration), and an organoid- and AI-based preclinical evaluation capability built through the 2025 absorption of Promedis and a $10M lead investment in Curi Bio.

The company's revenue model is predominantly B2B professional services priced via multi-year enterprise contracts on a quote basis, with revenue growing from 389 billion KRW (2022) to 666 billion KRW (FY2025), reaching 174 billion KRW in Q1 2026 (up 22.9% YoY). Customer segments are split between domestic and global pharmaceutical companies (enterprise field sales motion with named relationships including Eli Lilly, BMS, RealOne Medicines, and QingFeng) and Korean biotech companies that DreamCIS supports in clinical execution, global licensing, and investor relations (notably through the co-hosted Korea Integrated Investment & Licensing Forum with KDRA in 2026). Go-to-market is relationship-driven and targeted at biopharma decision-makers rather than broad marketing.

DreamCIS leverages parent Tigermed's global network spanning 50 countries and 29 networks to bridge Korean biotech sponsors into late-phase global trials, while pursuing inorganic growth through three sequential acquisitions: Medipen in 2022 (SMO, regulatory consulting, data management), Medipen SMO in 2024 (incorporating LSK Global PS SMO assets), and Promedis in 2025 (organoid and preclinical services). Strategic investments in Curi Bio (organoid) and Vertis (proteomics), plus ownership of the BGM0504 GLP-1/GIP dual-action obesity candidate (Phase 3 IND filed domestically), indicate an evolving strategy from pure-service CRO toward an integrated drug development and commercialization platform. Distribution is direct enterprise sales within Korea, channel-resold internationally through Tigermed.

Name

DreamCIS

Legal name

주식회사 드림씨아이에스

Website

https://dreamcis.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

DreamCIS is a KOSDAQ-listed South Korean full-lifecycle clinical research organization providing Phase 1-4 trials, SMO services, regulatory consulting, and organoid-based preclinical evaluation, serving pharmaceutical companies and Korean biotech firms through parent Tigermed's 50-country global network.

Ownership category

akta.pro rank

Product category

Clinical Research Organization (CRO) Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

Keywords

• Clinical research organization
• Clinical trial services
• Site management organization
• Regulatory consulting
• Organoid preclinical evaluation

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Development Services: Core CRO services including clinical trial design, execution, monitoring, and regulatory submission support. Revenue from clinical trial service contracts with biopharma companies.
2. Clinical Trial Support Services (SMO): Clinical site management, patient enrollment, and research conduct support through Medipen SMO. Revenue grew from 11 billion KRW in 2024 to 50 billion KRW in 2025, with 191.5% YoY growth in Q1 2026.
3. Consulting Services: Healthcare regulatory consulting, medical writing, data management, and statistical services through Medipen subsidiary.
4. Strategic Investments: Investment returns from leading Series B rounds in biotech companies like Curi Bio, generating potential capital gains and strategic partnerships.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

DreamCIS is a full-lifecycle clinical research organization (CRO) providing clinical trial design, execution, monitoring, and regulatory submission support across oncology, cardiovascular, endocrinology, and rare diseases. Through subsidiaries Medipen and Medipen SMO, the company delivers site management, patient enrollment, medical writing, data management, statistics, and healthcare regulatory consulting including IND and advanced therapy strategies. Promedice (acquired 2025) adds organoid-based preclinical evaluation and AI-driven drug development, while parent Tigermed's 50-country network enables multi-regional clinical trials (MRCTs) for Korean biotech and global pharma sponsors.

Product overview

DreamCIS operates as a full-lifecycle clinical development platform, evolving beyond traditional CRO services to offer integrated clinical development, regulatory consulting, and preclinical evaluation solutions. The core offering includes Clinical Development Services spanning Phase 1-4 trials, IIT, PMS, and medical device studies, supported by MediPinn SMO services acquired in 2022. Healthcare Regulatory Consulting provides IND preparation, regulatory strategy, and advanced therapy development support including cell therapy, gene therapy, and microbiome-based products. Strategic investments in organoid technology through Curi Bio and the BGM0504 obesity treatment pipeline represent new growth engines. The company leverages parent Tigermed's global network across 50 countries to connect domestic clinical trials to international markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Development Services Full-service CRO offering clinical trial design, execution, monitoring, and management across multiple therapeutic areas including oncology, cardiovascular, endocrinology, and rare diseases. Covers Phase 1-4 trials, IIT, PMS, NIS, and r-PMS studies for domestic and global pharmaceutical sponsors.
• Medipen SMO Services Site Management Organization services providing clinical trial site support, investigator coordination, and patient enrollment assistance. Delivered via Medipen (acquired 2022) and Medipen SMO (established 2024 with LSK Global PS SMO business rights); revenue grew from 11B KRW (2024) to 50B KRW (2025) with 191.5% YoY Q1 2026 growth.
• Medical Device Services Clinical development and regulatory consulting services for medical devices, supporting CE-MDR and FDA global registration strategies for medical device manufacturers entering or expanding in regulated markets.
• Healthcare Regulatory Consulting Comprehensive regulatory affairs support including IND preparation, drug approval strategy, clinical trial planning, medical writing, data management, and statistics. Includes advanced therapy product development consulting for cell therapy, gene therapy, and microbiome-based products.
• Organoid Preclinical Evaluation Services (Promedice) Organoid and AI-based preclinical evaluation services for drug discovery prediction, delivered through subsidiary Promedice (absorbed 2025). Supports the integrated preclinical-to-clinical value chain with engineered-tissue and high-resolution analytics across cardiac, skeletal muscle, neuromuscular, metabolic, and smooth muscle tissue applications.

Quantifiable outcome

• Achieved #1 domestic CRO revenue position in 2025 (connected basis)
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• MedipencoreStrategic or Co-development Partner · 1 January 2022Acquired in 2022, Medipen provides SMO services, Medical Writing, Data Management (DM), Statistics, and healthcare regulatory consulting. The acquisition expanded DreamCIS's business scope from traditional CRO into comprehensive clinical support services.
• KDRA (Korean Drug Developers Association)coreStrategic or Co-development PartnerCo-hosting the 2026 Korea Integrated Investment & Licensing Forum with KDRA. The forum brings together global pharma (Eli Lilly, BMS), investment firms (Temasek-Tigermed, B Capital, CMBI), and Korean biotech companies for investment and licensing discussions.
• Johns Hopkins UniversityflagshipStrategic or Co-development PartnerJohns Hopkins University hosts the Global Biotechnology Innovation Summit in Songdo, Incheon. DreamCIS presenting alongside Samsung Biologics and Celltrion as industry leaders. Forum covers organoids, AI-based drug development, biomanufacturing, and investment strategies.
• TigermedflagshipStrategic or Co-development PartnerParent company providing access to global clinical trial network spanning 50 countries. DreamCIS leverages Tigermed's 29-country, 50-network infrastructure to connect domestic Phase 1 trials to late-phase global trials for Korean biotech companies and serve as a bridge for international pharma.
• LSK Global PScoreStrategic or Co-development PartnerDreamCIS acquired LSK Global PS's SMO business rights in 2024, strengthening its clinical site management capabilities through Medipen SMO subsidiary.
• PromediscoreStrategic or Co-development PartnerAbsorbed via merger in 2024, Promedis is an organoid and preclinical evaluation company. The acquisition supports DreamCIS's strategy to build integrated preclinical-to-clinical value chain with AI and organoid-based platforms.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• IQVIA: Global #1 CRO with extensive Korean operations spanning clinical, real-world evidence, and technology-enabled trial services. Comparable on full-lifecycle clinical development but at vastly larger scale and broader therapeutic coverage than DreamCIS.
• WuXi AppTec: China-based global CRO/CDMO offering preclinical, clinical, and biologics services. Comparable on Asia-rooted full-lifecycle drug development, but WuXi has much broader scale, US/EU sites, and ongoing US legislative (BIOSECURE) headwinds.
• ICON plc: Global clinical CRO (post-PRA Health merger) with strong Asia-Pacific footprint including Korea. Overlaps with DreamCIS on Phase 1-4 trial execution, biotech/sponsor services, and lab services, but at substantially greater scale.
• Fortrea (Labcorp Drug Development spinoff): Global clinical CRO spun out of Labcorp in 2023, with Korean operations covering Phase 1-4 trials, biostatistics, and regulatory services. Direct overlap on clinical CRO services but with broader therapeutic area coverage and global scale.
• Parexel: Global mid-to-large clinical CRO with Korean operations covering Phase 1-4 trials, biopharma services, and regulatory consulting. Comparable full-lifecycle platform but with deeper therapeutic specialization and global sponsor relationships than DreamCIS.

Direct peers

• Medpace: Mid-sized, clinical-focused CRO with strong biotech customer base and full-service Phase 1-4 capabilities. Closely comparable business model — focused on clinical development services — though Medpace is larger and operates primarily in US/EU.
• Tigermed: Chinese-listed parent company and the largest clinical CRO in China, providing the 50-country global network DreamCIS leverages. Operates overlapping Phase 1-4 clinical trial services and serves as both supplier (referrals) and structural benchmark for valuation and capability comparison.
• Pharmaron: China-based CRO/CDMO with growing Korean and global clinical operations, covering preclinical through clinical services. Comparable integrated preclinical-to-clinical platform positioning, though Pharmaron has substantially larger preclinical/CMC scale.
• LSK Global PS: Korean-headquartered clinical CRO offering Phase 1-4 trial services, SMO, and biostatistics across the same therapeutic areas (oncology, cardiovascular, endocrinology). Direct domestic competitor — DreamCIS even acquired LSK Global PS's SMO business rights in 2024, underscoring the close overlap.

Emerging players

• Curi Bio: US-based preclinical platform using engineered tissue and organoid analytics for drug discovery. Strategic investee of DreamCIS ($10M Series B lead, Dec 2025) and integrated into DreamCIS's preclinical value chain via the Promedis subsidiary.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=yfeS3k2itvM
• LinkedInlinkedin.com/company/dreamcis

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DreamCIS